Angiotensinogen as a Therapeutic Target for Cardiovascular and Metabolic Diseases
Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-05 · 44 (5) · 1021-1030
DOI: 10.1161/atvbaha.124.318374 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-05. Verfasst von Alan Daugherty und 3 weiteren Autor:innen. Beteiligte Einrichtung: Saha Cardiovascular Research Center (A.D., H.S., M.B.S., H.S.L.), University of Kentucky, Lexington. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Angiotensinogen, Metabolic Diseases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
AGT (angiotensinogen) is the unique precursor for the generation of all the peptides of the renin-angiotensin system, but it has received relatively scant attention compared to many other renin-angiotensin system components. Focus on AGT has increased recently, particularly with the evolution of drugs to target the synthesis of the protein. AGT is a noninhibitory serpin that has several conserved domains in addition to the angiotensin II sequences at the N terminus. Increased study is needed on the structure-function relationship to resolve many unknowns regarding AGT metabolism. Constitutive whole-body genetic deletion of Agt in mice leads to multiple developmental defects creating a challenge to use these mice for mechanistic studies. This has been overcome by creating Agt -floxed mice to enable the development of cell-specific deficiencies that have provided considerable insight into a range of cardiovascular and associated diseases. This has been augmented by the recent development of pharmacological approaches targeting hepatocytes in humans to promote protracted inhibition of AGT synthesis. Genetic deletion or pharmacological inhibition of Agt has been demonstrated to be beneficial in a spectrum of diseases experimentally, including hypertension, atherosclerosis, aortic and superior mesenteric artery aneurysms, myocardial dysfunction, and hepatic steatosis. This review summarizes the findings of recent studies utilizing AGT manipulation as a therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Saha Cardiovascular Research Center (A.D., H.S., M.B.S., H.S.L.), University of Kentucky, Lexington.
- Saha Aortic Center (A.D., H.S., M.B.S., H.S.L.), University of Kentucky, Lexington.
- Department of Physiology (A.D., H.S., M.B.S., H.S.L.), University of Kentucky, Lexington.
- Department of Family and Community Medicine (M.B.S.), University of Kentucky, Lexington.
- Department of Surgery (M.B.S.), University of Kentucky, Lexington.
ORCID-Profile: Alan Daugherty, Hisashi Sawada, Mary B Sheppard, Hong S Lu
Förderung
- NHLBI NIH HHS
Zitieren
APA
Daugherty, A., Sawada, H., Sheppard, M. B., & Lu, H. S. (2024). Angiotensinogen as a Therapeutic Target for Cardiovascular and Metabolic Diseases. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(5), 1021-1030. https://doi.org/10.1161/atvbaha.124.318374
Vancouver
Daugherty A, Sawada H, Sheppard MB, Lu HS. Angiotensinogen as a Therapeutic Target for Cardiovascular and Metabolic Diseases. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(5):1021-1030. doi:10.1161/atvbaha.124.318374
BibTeX
@article{Daugherty2024,
author = {Daugherty, Alan and Sawada, Hisashi and Sheppard, Mary B and Lu, Hong S},
title = {Angiotensinogen as a Therapeutic Target for Cardiovascular and Metabolic Diseases},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2024},
volume = {44},
number = {5},
pages = {1021--1030},
doi = {10.1161/atvbaha.124.318374}
}
EUVIMED